Leonard Zehr, Author at BioTuesdays

Developments

iBio advances anti-CCR8 antibody program; looks forward to Roche RG6292 data

iBio (NYSEA:IBIO) advanced its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (GPCR) family, is expressed by T-regulatory cells (Tregs) that...

March 31, 2023

Feature

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.

March 28, 2023

Feature

Enveric taking new approach to mental health challenges

Enveric Biosciences (NASDAQ:ENVB) has created a library of more than 500 new chemical entities from its drug platform, including next generation psilocybin analogues for the treatment of anxiety, depression, and...

March 21, 2023

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Feature

Conavi’s Novasight shines new light on coronary interventions

Privately-held Conavi Medical’s Novasight Hybrid System represents a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.

March 7, 2023

Feature

AUM Biosciences focused on reversing cancer resistance

With two clinical and two preclinical assets, AUM Biosciences is developing precision oncology therapeutics designed to reverse cancer resistance through multi-targeting approaches.

February 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Developments

iBio selects MUC16 as next immuno-oncology target program

iBio (NYSE American:IBIO) selected MUC16 as the target of its latest immuno-oncology program. MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and...

February 17, 2023

Feature

Context Therapeutics advancing pipeline for female cancers and other tumors

Martin Lehr likes to use a baseball analogy to describe his company’s two cancer programs. “CTIM-76 is our hot young rookie with home run potential at every bat while ONA-XR is our veteran who consistently gets on...

February 14, 2023

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Author - Leonard Zehr

iBio advances anti-CCR8 antibody program; looks forward to Roche RG6292 data

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Enveric taking new approach to mental health challenges

bioAffinity rolling out CyPath for early detection of lung cancer

Conavi’s Novasight shines new light on coronary interventions

AUM Biosciences focused on reversing cancer resistance

Cognition Therapeutics focused on modifying degenerative disorders

iBio selects MUC16 as next immuno-oncology target program

Context Therapeutics advancing pipeline for female cancers and other tumors

Indaptus advancing Decoy20 against metastatic solid tumors

General

More